ROYAL BANK OF SCOTLAND GROUP PLC

Form FWP

November 27, 2012

Free Writing Prospectus Filed pursuant to Rule 433

dated November 27, 2012

(to Prospectus dated Registration Statement Nos. September 28, 2012 and 333-184147

Preliminary Prospectus Supplement dated November

27, 2012)

TERMS AND CONDITIONS

USD 2,250,000,000 6.125% Subordinated Tier 2 Notes due 2022

Issuer The Royal Bank of Scotland Group plc

Securities Subordinated Tier 2 Notes due 2022 (the "Notes")

Expected Security Ratings* BB+/BBB- (S&P/Fitch)

Ranking Subordinated

Principal Amount USD \$2,250,000,000

Price to the Public 99.923%

Specified Currency USD

Trade Date November 27, 2012

Settlement Date December 4, 2012 (T+5), in accordance with DTC's

procedures

Maturity December 15, 2022

Call Option No

Benchmark T 1.625% due November 15, 2022

Benchmark Yield 1.635%

Re-Offer Yield 6.135%

Re-Offer Spread to UST T+450 bps

Coupon 6.125%

Day Count 30/360

Convention Following, unadjusted
Business Days New York and London

Sole Structuring Advisor,

Joint Senior Bookrunner and

Joint Lead Manager

RBS Securities Inc.

Joint Senior Bookrunner and Morgan Stanley & Co. LLC

Joint Lead Manager

Joint Bookrunner and Joint Citigroup Global Markets Inc.

Lead Manager

Co-Managers ABN AMRO Securities (USA) LLC

Banca IMI S.p.A.

BMO Capital Markets Corp.

BNY Mellon Capital Markets, LLC

CIBC World Markets Corp. Commerz Markets LLC Danske Markets Inc Lloyds TSB Bank plc nabSecurities, LLC

Natixis Securities Americas LLC RBC Capital Markets, LLC

Santander Investment Securities Inc.

TD Securities (USA) LLC

Underwriting Discount 0.400%

Interest Payment Period Semi-Annual

Interest Payment Date(s) On the 15th day of each June and December, commencing on

June 15, 2013, up to and including December 15, 2022. The first interest payment period will be a long first coupon.

Interest Payment Record

Date(s)

On the 1st day of each June and December commencing on

June 1, 2013

Format SEC-Registered

Denominations USD \$2,000 and integral multiples of USD \$1,000 in excess

thereof

Listing An application will be made to list the notes on the New

York Stock Exchange

Clearing and Settlement DTC and Euroclear/Clearstream

CUSIP / ISIN 780099CE5 / US780099CE50

Governing Law New York (subordination and waiver of the right to set off

by holders governed by Scots Law)

Redemption for Tax Reasons Redemption at the principal amount of the Notes together

with accrued interest thereon, provided that, upon CRD IV (as defined below) taking effect in the United Kingdom, it shall only apply if, when and to the extent not prohibited by CRD IV and (in any such case) if, in the Issuer's opinion, the circumstance that entitles it to exercise such right of

redemption was not reasonably foreseeable to it at the Issue Date. The exercise of such right of redemption is conditional

on FSA consent/non-objection.

As used herein:

"CRD IV" means, taken together, (i) the CRD IV Directive, (ii)

the CRD IV Regulation and (iii) the Future Capital

Instruments Regulations;

"CRD IV Directive" means a directive of the European Parliament and of the Council on prudential requirements for credit institutions and investment firms amending Directive 2002/87/EC, a draft of which was published on July 20, 2011, and any successor directive;

"CRD IV Regulation" means a regulation of the European Parliament and of the Council on prudential requirements for

credit institutions and investment firms, a draft of which was published on July 20, 2011, and any successor regulation;

"FSA" means the Financial Services Authority and/or such other body having supervisory authority with respect to the Issuer: and

"Future Capital Instruments Regulations" means any regulatory capital rules, regulations or standards which are in the future applicable to the Issuer (on a solo or consolidated basis) and which lay down the requirements to be fulfilled by financial instruments for inclusion in the regulatory capital of the Issuer (on a solo or consolidated basis) as required by (i) the CRD IV Regulation and/or (ii) the CRD IV Directive.

Redemption due to Capital Disqualification Event

Redemption at par together with accrued interest thereon, provided that, upon CRD IV taking effect in the United Kingdom, it shall only apply if, when and to the extent not prohibited by CRD IV and (in any such case) if, in the Issuer's opinion, the circumstance that entitles it to exercise such right of redemption was not reasonably foreseeable to it at the Issue Date.

A "Capital Disqualification Event" shall be deemed to have occurred if, as a result of

any amendment to, or change in, the Capital Regulations which are in effect at the Issue Date, the Notes are fully excluded from Tier Two Capital (as defined in the Capital Regulations) of the Issuer and/or the Group.

The exercise of such right of redemption is conditional on FSA consent/non-objection.
As used herein:

"Capital Regulations" means, at any time, the regulations, requirements, guidelines and policies relating to capital adequacy of the FSA or of the European Parliament or of the Council of the European Union then in effect in the United Kingdom; and

"Group" means The Royal Bank of Scotland Group plc and its subsidiaries consolidated in accordance with International Financing Reporting Standards.

Applicable provided that, upon CRD IV taking effect in the United Kingdom, purchases are only permitted if, when and to the extent not prohibited by CRD IV.

The exercise of such right of redemption is conditional on FSA consent/non-objection.

The issuer has filed a registration statement (including a base prospectus) with the SEC for the offering to which this free writing prospectus relates. Before you invest in this offering, you should read the base prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, RBS Securities Inc. will arrange to send you the base prospectus at no charge if you request it by calling 1-866-884-2071.

Repurchases

^{*} The security ratings above are not a recommendation to buy, sell or hold the securities offered hereby. The ratings may be subject to revision or withdrawal at any time by S&P or Fitch.